卵巢癌患者胸腔积液的发病率、临床特征和预后。

IF 1.4 Q4 ONCOLOGY Pleura and Peritoneum Pub Date : 2021-03-24 eCollection Date: 2021-06-01 DOI:10.1515/pp-2020-0152
José M Porcel, Paola Murata, Laura Porcel, Silvia Bielsa, Marina Pardina, Antonieta Salud
{"title":"卵巢癌患者胸腔积液的发病率、临床特征和预后。","authors":"José M Porcel,&nbsp;Paola Murata,&nbsp;Laura Porcel,&nbsp;Silvia Bielsa,&nbsp;Marina Pardina,&nbsp;Antonieta Salud","doi":"10.1515/pp-2020-0152","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The prevalence, clinical characteristics and prognosis of pleural effusions (PEs) associated with ovarian cancer (OC) have seldom been addressed systematically, as in the current investigation.</p><p><strong>Methods: </strong>All records of consecutive women with a newly diagnosed OC in our institution over a 13-year period were retrospectively reviewed. Features of PEs on CT scans, pleural fluid analyses, need for definitive therapy of PEs, and the influence of PEs on the overall survival (OS) and progression-free survival (PFS) were evaluated.</p><p><strong>Results: </strong>PEs were observed in 81 (43%) of 189 women with OC, either at presentation of cancer (55 patients) or during the course of the disease (26 patients). The causes of PEs were malignancy (55.5%), unknown (37%), or surgery-related (7.4%). The sensitivity of the cytologic diagnosis of malignant PEs was 79.1%. Sixty percent of malignant PEs required pleurodesis or indwelling pleural catheters for symptomatic relief. The presence of ascites strongly predicted PE development (odds ratio 43.2). Women with PEs fared much worse compared with those without PEs, in terms of OS (26.7 vs. 90.4 months), PFS (9.8 vs. 55.3 months) and tumor recurrences (86.4 vs. 43%). In multivariate analyses, PE remained as a relevant independent variable associated with poor outcome (hazard ratio 9.73 for OS, and 3.87 for PFS). Notably, PEs small enough to preclude tapping, and thus of unknown origin, had a similar bad prognosis as malignant PEs.</p><p><strong>Conclusions: </strong>OC patients with PEs experience decreased survival, including those with trace effusions not amenable to tapping.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2021-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1515/pp-2020-0152","citationCount":"6","resultStr":"{\"title\":\"Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer.\",\"authors\":\"José M Porcel,&nbsp;Paola Murata,&nbsp;Laura Porcel,&nbsp;Silvia Bielsa,&nbsp;Marina Pardina,&nbsp;Antonieta Salud\",\"doi\":\"10.1515/pp-2020-0152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>The prevalence, clinical characteristics and prognosis of pleural effusions (PEs) associated with ovarian cancer (OC) have seldom been addressed systematically, as in the current investigation.</p><p><strong>Methods: </strong>All records of consecutive women with a newly diagnosed OC in our institution over a 13-year period were retrospectively reviewed. Features of PEs on CT scans, pleural fluid analyses, need for definitive therapy of PEs, and the influence of PEs on the overall survival (OS) and progression-free survival (PFS) were evaluated.</p><p><strong>Results: </strong>PEs were observed in 81 (43%) of 189 women with OC, either at presentation of cancer (55 patients) or during the course of the disease (26 patients). The causes of PEs were malignancy (55.5%), unknown (37%), or surgery-related (7.4%). The sensitivity of the cytologic diagnosis of malignant PEs was 79.1%. Sixty percent of malignant PEs required pleurodesis or indwelling pleural catheters for symptomatic relief. The presence of ascites strongly predicted PE development (odds ratio 43.2). Women with PEs fared much worse compared with those without PEs, in terms of OS (26.7 vs. 90.4 months), PFS (9.8 vs. 55.3 months) and tumor recurrences (86.4 vs. 43%). In multivariate analyses, PE remained as a relevant independent variable associated with poor outcome (hazard ratio 9.73 for OS, and 3.87 for PFS). Notably, PEs small enough to preclude tapping, and thus of unknown origin, had a similar bad prognosis as malignant PEs.</p><p><strong>Conclusions: </strong>OC patients with PEs experience decreased survival, including those with trace effusions not amenable to tapping.</p>\",\"PeriodicalId\":20231,\"journal\":{\"name\":\"Pleura and Peritoneum\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2021-03-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1515/pp-2020-0152\",\"citationCount\":\"6\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pleura and Peritoneum\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/pp-2020-0152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pleura and Peritoneum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/pp-2020-0152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/6/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 6

摘要

目的:与卵巢癌(OC)相关的胸腔积液(PEs)的患病率,临床特征和预后很少得到系统的解决,如在目前的调查中。方法:回顾性分析我院13年来所有新诊断为OC的连续女性患者的记录。评估了pe的CT扫描特征、胸膜液分析、pe明确治疗的必要性以及pe对总生存期(OS)和无进展生存期(PFS)的影响。结果:189例女性OC患者中有81例(43%)出现pe,包括癌初(55例)和病程(26例)。pe的病因包括恶性肿瘤(55.5%)、不明原因(37%)和手术相关(7.4%)。恶性PEs的细胞学诊断敏感性为79.1%。60%的恶性pe需要胸膜穿刺或留置胸膜导管来缓解症状。腹水的存在强烈预测PE的发展(优势比43.2)。在OS(26.7个月vs. 90.4个月)、PFS(9.8个月vs. 55.3个月)和肿瘤复发率(86.4个月vs. 43%)方面,有pe的女性比没有pe的女性表现更差。在多变量分析中,PE仍然是与预后不良相关的独立变量(OS的风险比为9.73,PFS的风险比为3.87)。值得注意的是,pe小到足以阻止穿刺,因此来源不明,与恶性pe有相似的不良预后。结论:合并pe的OC患者生存率降低,包括那些有微量积液的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer.

Objectives: The prevalence, clinical characteristics and prognosis of pleural effusions (PEs) associated with ovarian cancer (OC) have seldom been addressed systematically, as in the current investigation.

Methods: All records of consecutive women with a newly diagnosed OC in our institution over a 13-year period were retrospectively reviewed. Features of PEs on CT scans, pleural fluid analyses, need for definitive therapy of PEs, and the influence of PEs on the overall survival (OS) and progression-free survival (PFS) were evaluated.

Results: PEs were observed in 81 (43%) of 189 women with OC, either at presentation of cancer (55 patients) or during the course of the disease (26 patients). The causes of PEs were malignancy (55.5%), unknown (37%), or surgery-related (7.4%). The sensitivity of the cytologic diagnosis of malignant PEs was 79.1%. Sixty percent of malignant PEs required pleurodesis or indwelling pleural catheters for symptomatic relief. The presence of ascites strongly predicted PE development (odds ratio 43.2). Women with PEs fared much worse compared with those without PEs, in terms of OS (26.7 vs. 90.4 months), PFS (9.8 vs. 55.3 months) and tumor recurrences (86.4 vs. 43%). In multivariate analyses, PE remained as a relevant independent variable associated with poor outcome (hazard ratio 9.73 for OS, and 3.87 for PFS). Notably, PEs small enough to preclude tapping, and thus of unknown origin, had a similar bad prognosis as malignant PEs.

Conclusions: OC patients with PEs experience decreased survival, including those with trace effusions not amenable to tapping.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.50
自引率
11.10%
发文量
23
审稿时长
9 weeks
期刊最新文献
Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it? In vitro 3D microfluidic peritoneal metastatic colorectal cancer model for testing different oxaliplatin-based HIPEC regimens. Ascites does not accompany pleural effusion developing under dasatinib therapy in patients with CML-CP. Active surveillance for low-grade appendiceal mucinous neoplasm (LAMN) Peritoneal mestastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1